264 related articles for article (PubMed ID: 16529882)
41. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
42. Recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB). Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2005 Jan; 70(2):291-4. PubMed ID: 15630794
[TBL] [Abstract][Full Text] [Related]
43. Prescription opiate medications: medical uses and consequences, laws and controls.
Miller NS
Psychiatr Clin North Am; 2004 Dec; 27(4):689-708. PubMed ID: 15550288
[TBL] [Abstract][Full Text] [Related]
44. Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2001 Aug; 66(159):42943-4. PubMed ID: 11794309
[TBL] [Abstract][Full Text] [Related]
45. Schedule of controlled substances; placement of fospropofol into schedule IV. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2009 Oct; 74(192):51234-6. PubMed ID: 19877370
[TBL] [Abstract][Full Text] [Related]
46. Carisoprodol: update on abuse potential and legal status.
Reeves RR; Burke RS; Kose S
South Med J; 2012 Nov; 105(11):619-23. PubMed ID: 23128807
[TBL] [Abstract][Full Text] [Related]
47. New DEA rules expand options for controlled substance disposal.
Peterson DM
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):22-6. PubMed ID: 25607591
[TBL] [Abstract][Full Text] [Related]
48. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2011 Oct; 76(204):65371-5. PubMed ID: 22016903
[TBL] [Abstract][Full Text] [Related]
49. Drugs of Dependence Monitoring System: an effective check of the movements of certain drugs in Australia.
Murdoch DW
Bull Narc; 1983; 35(4):47-53. PubMed ID: 6563925
[TBL] [Abstract][Full Text] [Related]
50. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
[TBL] [Abstract][Full Text] [Related]
51. Drug-abuse deterrent formulations.
Wick JY
Consult Pharm; 2009 May; 24(5):356-62, 365. PubMed ID: 19555144
[TBL] [Abstract][Full Text] [Related]
52. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report.
Grudzinskas C; Balster RL; Gorodetzky CW; Griffiths RR; Henningfield JE; Johanson CE; Mansbach RS; McCormick CG; Schnoll SH; Strain EC; Wright C
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S77-82. PubMed ID: 16580154
[TBL] [Abstract][Full Text] [Related]
53. Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
Drug Enforcement Administration (DEA), Department of Justice
Fed Regist; 2003 Apr; 68(65):16427-30. PubMed ID: 12678045
[TBL] [Abstract][Full Text] [Related]
54. Current regulations and modest proposals regarding disposal of unused opioids and other controlled substances.
Herring ME; Shah SK; Shah SK; Gupta AK
J Am Osteopath Assoc; 2008 Jul; 108(7):338-43. PubMed ID: 18648027
[TBL] [Abstract][Full Text] [Related]
55. Abuse of prescription drugs and the risk of addiction.
Compton WM; Volkow ND
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S4-7. PubMed ID: 16563663
[TBL] [Abstract][Full Text] [Related]
56. National All Schedules Prescription Electronic Reporting Act (NASPER): balancing substance abuse and medical necessity.
Manchikanti L; Brown KR; Singh V
Pain Physician; 2002 Jul; 5(3):294-319. PubMed ID: 16902657
[TBL] [Abstract][Full Text] [Related]
57. Scheduling synthetic cathinone substances under the Controlled Substances Act.
Bonson KR; Dalton T; Chiapperino D
Psychopharmacology (Berl); 2019 Mar; 236(3):845-860. PubMed ID: 30969348
[TBL] [Abstract][Full Text] [Related]
58. Schedules of controlled substances: placement of ezogabine into Schedule V. Final rule.
Drug Enforcement Administration, Department of Justice
Fed Regist; 2011 Dec; 76(241):77895-99. PubMed ID: 22175093
[TBL] [Abstract][Full Text] [Related]
59. The necessity and utility of abuse liability evaluations in human subjects.
Vocci FJ
Br J Addict; 1991 Dec; 86(12):1537-42. PubMed ID: 1786484
[TBL] [Abstract][Full Text] [Related]
60. Does adherence monitoring reduce controlled substance abuse in chronic pain patients?
Manchikanti L; Manchukonda R; Damron KS; Brandon D; McManus CD; Cash K
Pain Physician; 2006 Jan; 9(1):57-60. PubMed ID: 16700282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
